Deksametasonin vaikutus postoperatiiviseen paranemiseen sekä elämänlaadun muuttuminen suusyöpäpotilaiden mikrovaskulaarisen rekonstruktioleikkauksen jälkeen

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-000892-11-FI

Enrollment

180

Registered

2008-07-14

Start date

2008-09-16

Completion date

Unknown

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suusyöpä MedDRA version: 9.1 Level: LLT Classification code 10030961 Term: Oral cancer stage unspecified

Interventions

Trade Name: Oradexon Product Name: Oradexon Pharmaceutical Form: Solution for injection INN or Proposed INN: DEXAMETHASONE CAS Number: 50022 Concentration unit: mg/ml milligram(s)/millilitre Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026